Dodge & Cox Reduces $84M in Regeneron Pharmaceuticals, Inc. ($REGN)
Key Points
- Dodge & Cox changed its Regeneron Pharmaceuticals, Inc. ($REGN) stake by 3.0% last quarter, cutting to 4,458,238 shares worth $2.72 billion.
- Wall Street's consensus rating on $REGN is Buy and an average price target of $833.31.
- $REGN last traded around $610.79.
Dodge & Cox trimmed its position in Regeneron Pharmaceuticals, Inc. ($REGN) by 3.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,458,238 shares of Regeneron Pharmaceuticals, Inc. after selling 138,120 shares during the quarter. Dodge & Cox's holdings in Regeneron Pharmaceuticals, Inc. were worth $2.72 billion as of its most recent filing.
Regeneron Pharmaceuticals, Inc. ($REGN) Stock
Regeneron Pharmaceuticals, Inc. Earnings
Regeneron Pharmaceuticals, Inc. Dividend
Analysts Set New Price Targets
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.